Masimo Analyst Ratings
Piper Sandler Upgrades Masimo to Overweight, Price Target at $160
Piper Sandler Maintains Neutral on Masimo, Raises Price Target to $126
Piper Sandler Keeps Their Hold Rating on Masimo (MASI)
Needham: Reiterates that Masimo (MASI.US) holds the rating.
Masimo Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Masimo (MASI), Halozyme (HALO) and McKesson (MCK)
Masimo's Strong Q1 Performance and Strategic Initiatives Prompt Buy Rating and $166 Price Target
Buy Rating Affirmed for Masimo Amidst Stable Financials and Strategic Business Optimism
Stifel Upgrades Masimo to Buy, Sees Room for Share Price Appreciation
Masimo Analyst Ratings
Buy Rating Affirmed for Masimo: Strategic Developments and Positive Outlook Signal Growth
Buy Rating Affirmed for Masimo Amid Strategic Split and Enhanced Profitability Outlook
Wells Fargo Upgrades Masimo to Overweight, Cites Spinoff Plan
Analysts Conflicted on These Healthcare Names: Masimo (MASI), ImmunityBio (IBRX) and Madrigal Pharmaceuticals (MDGL)
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR) and Masimo (MASI)
Masimo Analyst Ratings
Wells Fargo Upgrades Masimo to Overweight, Raises Price Target to $160
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), Masimo (MASI) and Johnson & Johnson (JNJ)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytokinetics (CYTK), Alphatec Holdings (ATEC) and Masimo (MASI)